
A groundbreaking preclinical study published in ACS Biomaterials Science & Engineering has revealed that nano-formulated ivermectin delivered intranasally reduced glioblastoma tumor size by 70 percent — at a dose lower than the approved human antiparasitic dose — all without a trace of toxicity in the brain, blood, or lungs















